-
Chiasma Plunges 60% Following FDA Review, CEO 'Surprised, Disappointed And Respectfully Disagree With The Decision'
Monday, April 18, 2016 - 10:34am | 354Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 60 percent Monday morning after the company provided an update regarding its New Drug Application for Mycapssa capsules. Chiasma is a biopharmaceutical company that focuses on treating patients with rare and serious chronic diseases. Its...
-
Chiasma Plunges 14%; Feuerstein Source Says FDA Will Reject Co.'s Therapy Capsules
Thursday, April 14, 2016 - 10:05am | 258Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 14 percent Thursday morning ahead of the U.S. Food and Drug Administration's decision on Friday to approve or reject the company's therapy. Chiasma is a biopharmaceutical company that focuses on the treatment of orphan diseases. The...
